Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies

Background Despite progress in cancer therapeutics, there remains an unmet need for treatment of advanced solid tumors. The cGAS-cGAMP-STING pathway plays a pivotal role in innate antitumor immunity processes. IMSA101 is a small molecule analog of cGAMP and a potent STING agonist. Preclinical studie...

Full description

Saved in:
Bibliographic Details
Main Authors: Syed Kazmi, Lijun Sun, Justin Moser, Angela Alistar, Timothy A Yap, Edward Garmey, Teresa Mooneyham, Peter Vu, Jay Jacoby, Deva Mahalingam
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/6/e011572.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items